Research report
A research report is the sourced material a domain
dossier is synthesized from — generated on a plan and a cadence, one topic per file.
A report carries no confidence tags. Its bracketed markers say who might have
an incentive to shade a line; none of them says anyone checked it. To reach a score, a line has
to be drafted onto a candidate as unverified and pass the Verifier or the
Corroborator, like everything else.
Section clinical-evidence · Version 2026-09-01 · Cadence quarterly · Evidence class mixed · Sources 10 · Supersedes none
Domain: pediatric-obstructive-sleep-apnea-testing · Scope: Peer-reviewed and trial-registry sources reachable by this repo's connectors, WebSearch
Sourcing: Rests on three independent professional-society/consensus documents
Three professional-society documents published between 2017 and 2020 — an AASM position paper, an AAO-HNS clinical practice guideline, and an IPOG Delphi consensus — independently agree that in-laboratory polysomnography (PSG) remains the diagnostic reference standard for pediatric obstructive sleep apnea, and none endorses an unattended home sleep apnea test (HSAT) as a substitute for pediatric diagnosis. The published comparative literature on limited-channel or peripheral-signal HSAT devices against PSG in children and adolescents is thin and, where it exists, direction-inconsistent: a 2026 systematic review restricts any favorable reliability finding to multichannel platforms carrying EEG and capnography, while every device-specific comparative study and completed sponsor validation trial located this pass reports substantial discordance rather than equivalence. The field's only large pediatric randomized controlled trial built around PSG-defined severity, the Childhood Adenotonsillectomy Trial (CHAT), did not reach significance on its own pre-specified primary neurocognitive outcome even though secondary behavioral, quality-of-life and polysomnographic measures improved. No post-2020 guideline update narrowing or rescinding the 2017 AASM HSAT position was located this pass.
_Baseline (v1). No prior version; this establishes the starting point for future diffs._
Three independent society-level documents converge on the same position. The AASM's 2017 task-force position paper states plainly: "Use of a home sleep apnea test is not recommended for the diagnosis of obstructive sleep apnea in children," a conclusion reached by an 8-expert task force after literature review and approved by the AASM Board of Directors [1]. The AAO-HNS's 2019 update to its Tonsillectomy in Children guideline treats PSG as the adjudicating test rather than an optional convenience: "Before performing tonsillectomy, the clinician should refer children with obstructive sleep-disordered breathing for polysomnography if they are <2 years of age or if they exhibit any of the following: obesity, Down syndrome, craniofacial abnormalities, neuromuscular disorders, sickle cell disease, or mucopolysaccharidoses," and separately, "Clinicians should recommend tonsillectomy for children with obstructive sleep apnea documented by overnight polysomnography" [single-source] [2]. The 2020 IPOG consensus statement, built on a two-round Delphi survey of 26 otolaryngologists, reached greater than 90% agreement on 15 items covering diagnosis and management of pediatric OSA "to be used along with existing clinical practice guidelines," without publishing the specific item wording in its structured abstract [single-source] [3]. Taken together, no society-level document located this pass endorses an unattended HSAT as a primary diagnostic substitute for PSG, and a direct search this pass for an AASM update after 2017 addressing limited-channel HSAT specifically returned nothing newer.
CHAT is a treatment trial, not a diagnostic-accuracy study, but it is the pivotal evidence behind treating PSG-defined severity as clinically meaningful in this population: eligibility, stratification and the trial's own polysomnographic outcome all rest on PSG. In 464 children aged 5–9 with OSA syndrome (AHI-qualified, without prolonged desaturation), randomized to early adenotonsillectomy versus watchful waiting with supportive care, the trial's own pre-specified primary outcome — change in attention/executive-function score — "did not differ significantly according to study group" (mean improvement 7.1±13.9 vs. 5.1±13.4, p=0.16). Secondary measures moved in favor of surgery: "significantly greater improvements in behavioral, quality-of-life, and polysomnographic findings," with normalization of polysomnographic findings (AHI<2) in 79% of the surgery group versus 46% of the watchful-waiting group [single-source] [4].
A 2026 systematic review of pediatric HSAT reliability, using the Cochrane risk-of-bias tool and JBI critical appraisal, found only 9 eligible studies, of which "only three studies employed simultaneous HSAT and PSG testing to evaluate the validity of HSAT indices." In its largest simultaneous comparison, mean AHI was "2.5 ± 3 for HSAT and 2.7 ± 2.9 for PSG (p > 0.05)," but the review's own conclusion narrows any endorsement: HSAT is "a reliable alternative to PSG when used with multiple channels, including EEG and capnography" [single-source] [5] — a channel set broader than a limited nasal-pressure/effort-belt/SpO2 montage.
Where a specific commercial device was tested against PSG in a US pediatric/adolescent cohort, the direction is negative. In 38 adolescents (mean age 15.5±1.6, BMI 97.7th percentile) with overweight or obesity, WatchPAT (peripheral arterial tonometry) showed a mean bias of 16.9±13.4 events/hour versus PSG-derived AHI, "overestimated OSA severity compared to PSG in 89% of participants," with sensitivity of 62–100% and specificity of only 5.5–32% across severity levels [single-source] [6]. ResMed's own completed validation trial of ApneaLink Air in adolescents (n=20, ages 12–17) posted results showing mean AHI of 6.2±10.7 on the home device versus 18.6±35.8 on in-lab PSG, with home testing technically successful in 15/20 (75%) versus 17/20 (85%) for the lab-equivalent comparator arm; 12 of 17 respondents (71%) reported preferring the home test [sponsor-reported] [7]. A separate Washington University feasibility trial of unattended home PSG in 11 children aged 5–12 found the home arm largely failed to collect usable data: only 1 of 10 evaluable participants reached the ≥6-hour data-adequacy threshold, three participants did not attempt the home test at all, and all 11 completed in-laboratory PSG [sponsor-reported] [8].
The Children's Hospital of Philadelphia's "Home Apnea Testing in CHildren Trial" (target enrollment 317, ESTIMATED, ages 5–12) is RECRUITING and has not posted results. Its secondary outcomes include "Proportion of participants who prefer HSAT to PSG" and "Association between therapeutic decision from HSAT compared to PSG" — registered intentions, not findings [sponsor-reported] [9].
[1] American Academy of Sleep Medicine Position Paper for the Use of a Home Sleep Apnea Test for the Diagnosis of OSA in Children — Journal of Clinical Sleep Medicine (published 2017, day not given in the PubMed record; accessed 2026-09-01). PMID 28877820 — https://pubmed.ncbi.nlm.nih.gov/28877820/ [guideline] [2] Clinical Practice Guideline: Tonsillectomy in Children (Update) — Otolaryngology–Head and Neck Surgery, American Academy of Otolaryngology–Head and Neck Surgery Foundation (published 2019, day not given in the PubMed record; accessed 2026-09-01). PMID 30798778 — https://pubmed.ncbi.nlm.nih.gov/30798778/ [guideline] [3] International Pediatric Otolaryngology group (IPOG) consensus on the diagnosis and management of pediatric obstructive sleep apnea (OSA) — International Journal of Pediatric Otorhinolaryngology (published 2020, day not given in the PubMed record; accessed 2026-09-01). PMID 32810686 — https://pubmed.ncbi.nlm.nih.gov/32810686/ [guideline] [4] A randomized trial of adenotonsillectomy for childhood sleep apnea — The New England Journal of Medicine (published 2013, day not given in the PubMed record; accessed 2026-09-01). PMID 23692173 — https://pubmed.ncbi.nlm.nih.gov/23692173/ [peer-reviewed] [5] Reliability of Home Sleep Apnea Test as a Diagnostic Modality in Children With Obstructive Sleep Apnea- a Systematic Review — Pediatric Pulmonology (published 2026-05, day not given in the PubMed record; accessed 2026-09-01). PMID 42165382 — https://pubmed.ncbi.nlm.nih.gov/42165382/ [peer-reviewed] [6] Comparison of WatchPAT to polysomnography measurement of apnea-hypopnea index and obstructive sleep apnea severity in adolescents with overweight and obesity — Journal of Clinical Sleep Medicine (published 2025-04-01; accessed 2026-09-01). PMID 39745453 — https://pubmed.ncbi.nlm.nih.gov/39745453/ [peer-reviewed] [7] Validation of ApneaLink Air Home Sleep Testing in the Diagnosis of Obstructive Sleep Apnea in Adolescent Children — ClinicalTrials.gov, sponsor ResMed (posted results; record last updated 2021-11-15; accessed 2026-09-01). NCT03748771 — https://clinicaltrials.gov/study/NCT03748771 [trial-registry] [8] Feasibility of Unattended Home Polysomnography and Comparison to In-laboratory Polysomnography in Pediatric Patients — ClinicalTrials.gov, sponsor Washington University School of Medicine (posted results; record last updated 2024-02-07; accessed 2026-09-01). NCT03473548 — https://clinicaltrials.gov/study/NCT03473548 [trial-registry] [9] Home Apnea Testing in CHildren Trial — ClinicalTrials.gov, sponsor Children's Hospital of Philadelphia (record last updated 2026-04-21; no results posted; accessed 2026-09-01). NCT05382754 — https://clinicaltrials.gov/study/NCT05382754 [trial-registry] [10] Diagnosis and management of childhood obstructive sleep apnea syndrome — Pediatrics, American Academy of Pediatrics technical report (published 2012, day not given in the PubMed record; accessed 2026-09-01). PMID 22926176 — https://pubmed.ncbi.nlm.nih.gov/22926176/ [guideline]
Well established: That PSG is the professional-society reference standard and that no current guideline endorses unattended HSAT for primary pediatric diagnosis rests on three independent, non-affiliated documents — AASM [1], AAO-HNS [2], and the American Academy of Pediatrics technical report [10] — with the 2020 IPOG consensus [3] as a fourth, later corroborating position. This is the one line in this report carrying no marker.
Thin: Every quantitative effect size and every device-specific comparison in section 3 rests on exactly one source: the CHAT trial [4], the systematic review [5], the WatchPAT study [6], and both completed trial results [7][8] are each [single-source] or [sponsor-reported]. No two independent groups have published concordant AHI-agreement data on the same commercial device in a US pediatric or adolescent cohort. The IPOG consensus's specific 15 items [3] were not read past the structured abstract.
Rescoped from class 3: "Would parents/clinicians prefer a home test to an in-lab study for their child?" is not answerable. Its revealed-behaviour twin — what a completed trial's respondents actually reported when asked — has now partially reported: 12 of 17 respondents (71%) in ResMed's ApneaLink Air adolescent trial said they preferred the home test over PSG [sponsor-reported] [7]. A second, larger registered trial (NCT05382754) has the same question as a secondary outcome and has not yet reported [sponsor-reported] [9].
Out of scope: 510(k) clearance status, product codes, and recall history for named devices (WatchPAT, ApneaLink, SNAP Diagnostics SAM) — covered by this domain's reference-products section, not reproduced here. HCPCS/CPT coding and payer coverage policy were not researched under this report's clinical-evidence scope. MAUDE complaint narratives were not searched — no connector reaches MAUDE in this repository.
Not searched vs. not found: A post-2020 AASM, AAP, or AAO-HNS update specifically addressing limited-channel pediatric HSAT was searched for directly this pass (three separate query formulations) and not found — the 2017 AASM position paper remains the most recent society-level statement located. Full text of the AAO-HNS [2] and IPOG [3] documents beyond their PubMed structured abstracts was not searched this pass (both are typically paywalled at the publisher). A pediatric HSAT-versus-PSG study using two or more independent research groups on the same device was searched for and not found in this pass's query set.
[inference] The pattern across every device-specific comparison located this pass — WatchPAT overestimating severity in adolescents [6], ApneaLink Air understating PSG-derived AHI by roughly a factor of three in a small adolescent sample [7], and a home-PSG feasibility arm that mostly failed to collect data at all [8] — is consistent with, but does not by itself confirm, the 2017 AASM task force's specific stated concern about HSAT devices lacking CO2 and arousal-detection channels. None of the three studies tested a device with those channels, so this report cannot distinguish "limited-channel HSAT is inherently less accurate in children" from "these three specific devices/cohorts underperformed" [inference].
| Proposition | Evidence class | Resolvable identifier | Dossier section |
|---|---|---|---|
| The AASM's 2017 task-force position paper states that home sleep apnea testing "is not recommended for the diagnosis of obstructive sleep apnea in children" | 2 published | PMID 28877820 | Standard of care & clinical evidence |
| The AAO-HNS's 2019 Tonsillectomy in Children guideline requires PSG referral before tonsillectomy for children under 2 years or with obesity, Down syndrome, craniofacial abnormalities, neuromuscular disorders, sickle cell disease, or mucopolysaccharidoses | 2 published | PMID 30798778 | Standard of care & clinical evidence |
| In the CHAT trial (n=464, ages 5–9), the primary neurocognitive outcome did not differ significantly between early adenotonsillectomy and watchful waiting (mean improvement 7.1±13.9 vs. 5.1±13.4, p=0.16), while PSG normalization occurred in 79% vs. 46% of groups respectively | 2 published | PMID 23692173 | Standard of care & clinical evidence |
| In a 38-adolescent cohort with overweight/obesity, WatchPAT overestimated OSA severity relative to PSG in 89% of participants, with specificity of 5.5–32% across severity levels | 2 published | PMID 39745453 | Reference products |
| ResMed's completed ApneaLink Air adolescent validation trial (n=20, ages 12-17) posted a mean AHI of 6.2±10.7 events/hour on the home device versus 18.6±35.8 on in-lab PSG | 1 registry | NCT03748771 | Reference products |
| A Washington University feasibility trial of unattended home PSG in children (n=11, ages 5–12) found only 1 of 10 evaluable participants reached ≥6 hours of usable recorded data | 1 registry | NCT03473548 | Reference products |